Q&A: HDV Management Episode 2

In this episode, Tatyana Kushner, MD, MSCE, and Stefan Zeuzem, MD, address key considerations when screening, diagnosing, and treating patients with HDV, such as:

• Barriers to HDV screening, including limitations to AASLD guideline recommendations
• Use of double reflex testing to improve HDV diagnosis
• Considerations for repeat HDV testing in patients who are HBsAg positive who previously tested negative for HDV
• Updated CDC recommendations for HBV screening for all adults using a triple panel test 
• Staging advanced liver disease in patients with HDV
• Indications for HDV treatment, including patients with low ALT levels and advanced or progressive liver disease
• Treatment landscape for HDV
• Personal experiences with use of pegylated interferon for HDV treatment, including considerations for use in patients with compensated cirrhosis
• Updates on novel HDV therapies, including:
  • Summary of efficacy data on bulevirtide from clinical trials
  • Interpretation of results from D-LIVR, a phase III trial assessing the safety and efficacy of lonafarnib 

Link to full program: 
bit.ly/3yp1Lxf

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.